Insider · CIK 0001727606
Eiry Roberts
officerdirector
Files at BHC (Bausch Health Companies Inc.), NBIX (NEUROCRINE BIOSCIENCES INC), FOLD (AMICUS THERAPEUTICS, INC.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 14, 2025 | NBIX NEUROCRINE BIOSCIENCES, INC. | 500 0.00% of outstanding | $58k | Feb 14, 2025 | $441k |
| Feb 13, 2025 | NBIX NEUROCRINE BIOSCIENCES, INC. | 1,114 0.00% of outstanding | $131k | Feb 13, 2025 | $338k |
| Feb 13, 2025 | NBIX NEUROCRINE BIOSCIENCES, INC. | 604 0.00% of outstanding | $71k | Feb 13, 2025 | $338k |
| Feb 10, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | 980 0.00% of outstanding | $120k | Feb 10, 2025 | $223k |
| Jan 31, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | 1,457 0.00% of outstanding | $223k | Jan 31, 2025 | none |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | BHC Bausch Health Companies Inc. | AGrant or award Common Shares, No Par Value | +45,871 | $0.00 | $0 | 45,871 | May 26, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Common Stock | -76,275 | $14.50 | $1.1M | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -40,625 | - | - | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -45,423 | - | - | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -30,474 | - | - | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -42,467 | - | - | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -74,872 | - | - | 0 | Apr 27, 2026 |
| Jun 5, 2025 | FOLD AMICUS THERAPEUTICS, INC. | AGrant or award Common Stock | +20,414 | $0.00 | $0 | 76,275 | Jun 6, 2025 |
| Jun 5, 2025 | FOLD AMICUS THERAPEUTICS, INC. | AGrant or award Stock Options (right to buy)derivative | +74,872 | $0.00 | $0 | 74,872 | Jun 6, 2025 |
| Dec 17, 2024 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Restricted Stock Unitderivative | +5,487 | $0.00 | $0 | 5,487 | Dec 19, 2024 |
| Dec 17, 2024 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Stock Optionderivative | +27,770 | $0.00 | $0 | 27,770 | Dec 19, 2024 |
| Nov 8, 2024 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock | +5,140 | $77.81 | $400k | 28,856 | Nov 12, 2024 |
| Nov 8, 2024 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock | +1,233 | $81.05 | $100k | 30,089 | Nov 12, 2024 |
| Nov 8, 2024 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock | +971 | $102.90 | $100k | 31,060 | Nov 12, 2024 |
| Nov 8, 2024 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock | +1 | $79.02 | $79 | 31,061 | Nov 12, 2024 |
| Nov 8, 2024 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Incentive Stock Optionderivative | -5,140 | $0.00 | $0 | 0 | Nov 12, 2024 |
| Nov 8, 2024 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Incentive Stock Optionderivative | -1,233 | $0.00 | $0 | 0 | Nov 12, 2024 |
| Nov 8, 2024 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Incentive Stock Optionderivative | -971 | $0.00 | $0 | 0 | Nov 12, 2024 |
| Nov 8, 2024 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Incentive Stock Optionderivative | -1 | $0.00 | $0 | 1,265 | Nov 12, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.